Compare SIGA & NHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SIGA | NHS |
|---|---|---|
| Founded | 1995 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 223.8M | 251.6M |
| IPO Year | 2016 | N/A |
| Metric | SIGA | NHS |
|---|---|---|
| Price | $3.06 | $5.97 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 607.7K | 153.8K |
| Earning Date | 05-05-2026 | 01-01-0001 |
| Dividend Yield | 13.24% | ★ 13.44% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $224.81 | N/A |
| P/E Ratio | $23.54 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.83 | $5.91 |
| 52 Week High | $9.45 | $7.75 |
| Indicator | SIGA | NHS |
|---|---|---|
| Relative Strength Index (RSI) | 44.02 | 41.02 |
| Support Level | $3.01 | $5.91 |
| Resistance Level | $4.84 | $6.12 |
| Average True Range (ATR) | 0.13 | 0.05 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 68.97 | 30.00 |
SIGA Technologies Inc a commercial-stage pharmaceutical company. The Company sells its product, TPOX oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets, to the U.S. Government and international governments (including government-affiliated entities). The Company operates in one single operating and reportable segment, which includes all activities related to the sale of the Company's Oral and IV TPOXX as well as research and development services.
Neuberger Berman High Yield Strategies Fund Inc is a diversified, closed-end management investment company. The company invests in high yield debt securities market. The Fund uses leverage to pursue its investment objective. The Fund may invest in a variety of direct debt instruments, including bank loans, notes and other interests in amounts owed to financial institutions by borrowers, such as companies and governments. Corporate loans in which the Fund may invest will consist of direct obligations of borrowers. The Fund may invest in corporate loans at origination as a co-lender or may acquire loans in the secondary market by purchasing participations in, assignments of or novations of corporate loans.